Prostate cancer incidence in males with Lynch syndrome

Genetics in Medicine

Volumn 16, Issue 7, 2014, Pages 553-557

  Haraldsdottir, Sigurdis ^a   Hampel, Heather ^b   Wei, Lai ^b   Wu, Christina ^a   Frankel, Wendy ^a   Bekaii Saab, Tanios ^a   De La Chapelle, Albert ^a   Goldberg, Richard M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b University Medical Center   (United States)

Author keywords

Colorectal cancer; Lynch syndrome; Microsatellite instability; Mismatch repair deficiency; Prostate cancer

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR; PHENOTYPE; POPULATION; PROSTATE CANCER; VERY ELDERLY; ADOLESCENT; CHILD; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPLICATION; DNA REPAIR; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; INCIDENCE; METABOLISM; MUTATION; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY; YOUNG ADULT;

ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; DNA LIGASE; G-T MISMATCH-BINDING PROTEIN; MICROSATELLITE DNA; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHILD; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84903789096     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.193     Document Type: Article

References (26)

1. Comprehensive molecular characterization of human colon and rectal cancer Nature 2012 487 330-337
2. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNAmismatch- repair genes. Int J Cancer 1999;81:214-218.
3. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
4. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354: 261-269.
5. Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012;104:1363-1372.
6. Grindedal EM, MOøller P, Eeles R, et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2460-2467.
7. Raymond VM, Mukherjee B, Wang F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013;31:1713-1718.
8. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409-4415.
9. Pande M, Wei C, Chen J, et al. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Fam Cancer 2012;11:441-447.
10. Scott RJ, McPhillips M, Meldrum CJ, et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 2001;68:118-127.
11. Soravia C, van der Klift H, Bründler MA, et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 2003;121A:159-162.
12. Ahman AK, Jonsson BA, Damber JE, Bergh A, Grönberg H. Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int 2001;87:334-338.
13. Bauer CM, Ray AM, Halstead-Nussloch BA, et al. Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 2011;10:37-42.
14. Lotsari JE, Gylling A, Abdel-Rahman WM, et al. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, noncarriers, and sporadic cases. Breast Cancer Res 2012;14:R90.
15. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381.
17. Wolf AM, Wender RC, Etzioni RB, et al.; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
18. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851- 1860.
19. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783- 5788.
20. Clendenning M, Senter L, Hampel H, et al. A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. J Med Genet 2008;45:340-345.
21. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135:419- 428.e411.
22. United States Department of Health and Human Services CfDCaPaNCI. United States Cancer Statistics: 1999 - 2009 Incidence, WONDER Online Database. http://wonder.cdc.gov/cancer-v2009.htmlAccessed25May2013
23. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975- 2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. http//seercancer.gov/csr/1975-2009-pops09/. 2012; based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
24. Goecke T, Schulmann K, Engel C, et al.; German HNPCC Consortium. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006;24:4285-4292.
25. Barrow PJ, Ingham S, O'Hara C, et al. The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013;12:57-63.
26. IMPACT. Targeted Prostate Cancer Screening Study. http://www.impact- study.co.uk/.Accessed8June2013.